TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

EXHIBIT 99.1 Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy. Q2 2025 shows 10th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in

Amendment No. 1, dated as of June 5, 2025, to the Employment Agreement between Teva Pharmaceutical Industries Limited and Richard D. Francis *

Exhibit 10.1 Execution Version Amendment No. 1 to Employment Agreement This Amendment to the Employment Agreement (the “Amendment”) is entered into on this 5 day of June 2025 (the “Effective Amendment Date”) and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 124 Dvora HaNevi’a Street, Tel Aviv, Israel, Company No. 52-001395-4 (the “Company” or “Teva”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT T

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorporati

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2025 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorporatio

Exhibit 1.01 – Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form

Exhibit 1.01 Teva Pharmaceutical Industries Limited Conflict Minerals Report For the Year Ended December 31, 2024 This Specialized Disclosure Report on Form SD of Teva Pharmaceutical Industries Limited for the year ended December 31, 2024 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdict

SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 124 Dvora HaNevi’a St., Tel Aviv, Israel 6944020 (

Consent of Van Doorne N.V. (included in Exhibit 5.3)

EX-5.3 Exhibit 5.3 Teva Pharmaceutical Finance Netherlands II B.V. T +31 20 6789 123 Teva Pharmaceutical Finance Netherlands III B.V. F +31 20 6789 589 Teva Pharmaceutical Finance Netherlands IV B.V. c/o Teva Pharmaceutical Industries Limited 124 Dvora Hanevi’a Street Tel Aviv, 6944020 Israel Date Dear Sirs, Madams, 28 May 2025 Our ref. 40003173 Subject Registration Statement on Form S-3 ASR re: T

Fifth Supplemental Senior Indenture, dated as of May 28, 2025, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent.

Exhibit 4.2 TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, THE BANK OF NEW YORK MELLON, as Trustee and THE BANK OF NEW YORK MELLON, LONDON BRANCH, as Paying Agent FIFTH SUPPLEMENTAL SENIOR INDENTURE Dated as of May 28, 2025 to the Senior Indenture dated as of March 14, 2018 Creating the series of Securities (as defined herein) desi

First Supplemental Senior Indenture, dated as of May 28, 2025, among Teva Pharmaceutical Finance Netherlands IV B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.

EX-4.8 Exhibit 4.8 TEVA PHARMACEUTICAL FINANCE NETHERLANDS IV B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, and THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL SENIOR INDENTURE Dated as of May 28, 2025 to the Senior Indenture dated as of May 28, 2025 Creating the series of Securities (as defined herein) designated 5.750% Senior Notes due 2030 TABLE OF CONTENTS P

Senior Indenture, dated as of May 28, 2025, among Teva Pharmaceutical Finance Netherlands IV B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.

EX-4.7 Exhibit 4.7 TEVA PHARMACEUTICAL FINANCE NETHERLANDS IV B.V., as Issuer TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor and THE BANK OF NEW YORK MELLON, as Trustee SENIOR INDENTURE Dated as of May 28, 2025 Table of Contents Page ARTICLE 1 DEFINITIONS Section 1.01 Certain Terms Defined 1 ARTICLE 2 SECURITIES Section 2.01 Forms Generally 5 Section 2.02 Form of Trustee’s Certification of A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2025 TEVA PHARMACEUTICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2025 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of incorporation

Fifth Supplemental Senior Indenture, dated as of May 28, 2025, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.

Exhibit 4.5 TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, and THE BANK OF NEW YORK MELLON, as Trustee FIFTH SUPPLEMENTAL SENIOR INDENTURE Dated as of May 28, 2025 to the Senior Indenture dated as of March 14, 2018 Creating the series of Securities (as defined herein) designated 6.000% Senior Notes due 2032 TABLE OF CONTENTS Page

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes Proceeds to Repay Existing Debt

Exhibit 99.1 Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes Proceeds to Repay Existing Debt TEL AVIV, Israel—(BUSINESS WIRE)— Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amo

CALCULATION OF THE REGISTRATION FEE

Exhibit 107 CALCULATION OF THE REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price per Security Proposed Maximum Aggregate Offering Price Amount of Registration Fee €1,000,000,000 4.

$2,300,000,000 (equivalent) Teva Pharmaceutical Finance Netherlands II B.V. €1,000,000,000 4.125% Senior Notes due 2031 Teva Pharmaceutical Finance Netherlands III B.V. $500,000,000 6.000% Senior Notes due 2032 Teva Pharmaceutical Finance Netherlands

Filed Pursuant to Rule 424(b)(5) Registration No. 333-284770 PROSPECTUS SUPPLEMENT (To Prospectus dated February 7, 2025) $2,300,000,000 (equivalent) Teva Pharmaceutical Finance Netherlands II B.V. €1,000,000,000 4.125% Senior Notes due 2031 Teva Pharmaceutical Finance Netherlands III B.V. $500,000,000 6.000% Senior Notes due 2032 Teva Pharmaceutical Finance Netherlands IV B.V. $700,000,000 5.750%

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2025 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of incorporation

Underwriting Agreement, dated as of May 20, 2025, among the Issuers, the Company, BNP PARIBAS, BNP Paribas Securities Corp., BofA Securities Europe SA, BofA Securities, Inc., HSBC Bank plc, HSBC Continental Europe, Intesa Sanpaolo S.p.A. and J.P. Morgan SE as representatives for the underwriters named in Schedule 1 annexed thereto.

Exhibit 1.1 TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. €1,000,000,000 4.125% Senior Notes due 2031 TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. $500,000,000 6.000% Senior Notes due 2032 TEVA PHARMACEUTICAL FINANCE NETHERLANDS IV B.V. $700,000,000 5.750% Senior Notes due 2030 Payment of principal and interest unconditionally guaranteed by TEVA PHARMACEUTICAL INDUSTRIES LIMITED UNDERWRITING

FREE WRITING PROSPECTUS DATED May 20, 2025 (To the Prospectus dated February 7, 2025, as supplemented by the Preliminary Prospectus Supplement dated May 19, 2025) Teva Pharmaceutical Finance Netherlands II B.V. €1,000,000,000 4.125% Senior Notes due

FWP ISSUER FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration No. 333-284770 May 20, 2025 FREE WRITING PROSPECTUS DATED May 20, 2025 (To the Prospectus dated February 7, 2025, as supplemented by the Preliminary Prospectus Supplement dated May 19, 2025) Teva Pharmaceutical Finance Netherlands II B.V. €1,000,000,000 4.125% Senior Notes due 2031 Teva Pharmaceutical Finance Netherlands II

Subject to Completion Preliminary Prospectus Supplement, dated May 19, 2025

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-284770 INFORMATION IN THIS PRELIMINARY PROSPECTUS SUPPLEMENT IS NOT COMPLETE AND MAY BE CHANGED. THE DEFINITIVE TERMS OF THE TRANSACTIONS DESCRIBED HEREIN WILL BE DESCRIBED IN THE FINAL VERSION OF THIS DOCUMENT. THIS PRELIMINARY PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS ARE NOT AN OFFER TO SELL THESE SECURITIES AND

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

EXHIBIT 99.1 Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues reco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 TEVA PHARMACEUTICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITE

April 14, 2025

April 14, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands III B.V. Subordinated Indenture

Exhibit 25.12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands IV B.V. Subordinated Indenture

Exhibit 25.14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Industries Limited Subordinated Indenture

Exhibit 25.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance IV, LLC Senior Indenture

Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

As filed with the Securities and Exchange Commission on February 7, 2025

Table of Contents As filed with the Securities and Exchange Commission on February 7, 2025 Registration No.

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the Senior Indenture, dated as of March 14, 2018, by and among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.

Exhibit 25.15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance V, LLC Subordinated Indenture

Exhibit 25.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands II B.V. Subordinated Indenture

Exhibit 25.10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance V, LLC Senior Indenture

Exhibit 25.5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINEELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Jur

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands II B.V. Senior Indenture

Exhibit 25.9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the Senior Indenture, dated as of March 14, 2018, by and among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee

Exhibit 25.16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Industries Limited Senior Indenture

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance VI, LLC Senior Indenture

Exhibit 25.7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands IV B.V. Senior Indenture

Exhibit 25.13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance IV, LLC Subordinated Indenture

Exhibit 25.4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Consent of Van Doorne, N.V. (included in Exhibit 5.3)

EX-5.3 Exhibit 5.3 Teva Pharmaceutical Finance Netherlands II B.V. Teva Pharmaceutical Finance Netherlands III B.V. Teva Pharmaceutical Finance Netherlands IV B.V. c/o Teva Pharmaceutical Industries Limited 124 Dvora Hanevi’a Street Tel Aviv 6944020 Israel Date Dear Addressees, 7 February 2025 Our ref. 40.00.3000 Subject Registration Statement Form S-3 We have acted as Dutch legal advisers to Teva

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance VI, LLC Subordinated Indenture

Exhibit 25.8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 ASR (Form Type) Teva Pharmaceutical Industries Limited Teva Pharmaceutical Finance IV, LLC Teva Pharmaceutical Finance V, LLC Teva Pharmaceutical Finance VI, LLC Teva Pharmaceutical Finance Netherlands II B.

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands III B.V. Senior Indenture

Exhibit 25.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Employment Agreement, dated as of June 14, 2022, between Teva Pharmaceutical Industries Limited and Eric A. Hughes *

EX-10.8 Exhibit 10.8 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of June 14, 2022 (the “Execution Date”), is entered into by and between TEVA PHARMACEUTICALS USA, INC., a Delaware corporation (“Teva USA”), and ERIC HUGHES (the “Executive”). R E C I T A L S: WHEREAS, Teva USA desires to employ the Executive and the Executive has indicated his willin

Subsidiaries of the Registrant *

Exhibit 21 The following is a list of subsidiaries of the Company as of December 31, 2024, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.

Employment Agreement, dated as of September 19, 2023, between Teva Pharmaceutical Industries Limited and Christine Fox *

Exhibit 10.20 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of September 19, 2023 (the “Execution Date”), is entered into by and between TEVA PHARMACEUTICALS USA, INC., a Delaware corporation (“Teva USA”), and CHRISTINE FOX (the “Executive”). R E C I T A L S: WHEREAS, Teva USA desires to employ the Executive and the Executive has indicated her willin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from     to      Commission file number 0

Form Award Agreement (RSUs and PSUs) under the Teva Pharmaceutical Industries Limited 2020 Long-Term Equity-Based Incentive *

EX-10.23 Exhibit 10.23 TEVA PHARMACEUTICAL INDUSTRIES LIMITED AWARD AGREEMENT This Award Agreement (this “Agreement”), is made effective as of [•], between Teva Pharmaceutical Industries Limited (the “Company”) and [•] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2020 Long-Term Equity-Based Incentive Plan (th

Teva Insider Trading Policy and Procedure and Teva Addendum to Insider Trading Policy *

Exhibit 19 Effective: November, 2024 Insider Trading Policy and Procedure Purpose and Scope The purpose of this policy (“Policy”) is to establish the principles and expectations of Teva Pharmaceutical Industries Limited and its subsidiaries (collectively, “Teva”) with respect to insider trading laws and other applicable securities laws and regulations regarding trading in securities.

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

EXHIBIT 99.1 Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth 2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO® - exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY® - global annual revenues

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 TEVA PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2024 TEVA PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LI

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorpor

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

EXHIBIT 99.1 Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in lo

English summary of Tax Settlement Agreement, dated June 23, 2024, between Teva Pharmaceutical Industries Limited and the Israeli Tax Authorities *

Exhibit 10.2 English summary of Tax Settlement Agreement, dated June 23, 2024, between Teva Pharmaceutical Industries Limited and the Israeli Tax Authorities (the “Agreement”) Parties: (a) Assessing Officer Jerusalem 1 (the “Assessing Officer”); and (b) Teva Pharmaceutical Industries Ltd. (the “Parent Company”), Assia Chemical Industries Ltd. (“Assia”), Teva Medical Ltd. (“Teva Medical”), Plantex

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance

EXHIBIT 99.1 Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency terms compared to Q2 2023. Generics business grows ac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT T

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorporati

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 TEVA PHARMACEUTICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorporatio

Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form

Exhibit 1.01 Teva Pharmaceutical Industries Limited Conflict Minerals Report For the Year Ended December 31, 2023 This Specialized Disclosure Report on Form SD of Teva Pharmaceutical Industries Limited for the year ended December 31, 2023 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdict

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 124 Dvora HaNevi’a St., Tel Aviv, Israel 6944020 (Add

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorporatio

TEVA ANNOUNCES APPOINTMENT OF MATTHEW SHIELDS TO EXECUTIVE VICE PRESIDENT, TEVA GLOBAL OPERATIONS

Exhibit 99.1 TEVA ANNOUNCES APPOINTMENT OF MATTHEW SHIELDS TO EXECUTIVE VICE PRESIDENT, TEVA GLOBAL OPERATIONS TEL AVIV, Israel, May 15, 2024, BUSINESS WIRE– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024.

Page 2 of 14

EX-99.1 Exhibit 99.1 For an accessible version of this Press Release, please visit www.tevapharm.com TEVA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS 2024 FINANCIAL OUTLOOK • Generics business and AUSTEDO® growth lead Q1 2024 performance. • Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. • Generics business growth across all r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2024 TEVA PHARMACEUTICAL IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction of Incorporation) (Co

Second Amendment to Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated May 3, 2024, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., and Bank of America, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on May 8, 2024)

Exhibit 10.1 SECOND AMENDMENT TO SENIOR UNSECURED SUSTAINABILITY-LINKED REVOLVING CREDIT AGREEMENT This AMENDMENT to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated as of May 3, 2024 (this “Amendment”), is made and entered into by and among TEVA PHARMACEUTICAL INDUSTRIES LIMITED, an Israeli company registered under no 52-0013-954, the registered address of which is at

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 18, 2024 TEVA PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 18, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorporat

The following tables present revenues by major products and activities for each segment for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023: United Stat

Exhibit 99.1 The following tables present revenues, expenses and profit for each segment for the years ended December 31, 2023 and 2022, and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023: United States Segment Year ended December 31, Three months ended 2023 2022 December 31, September 30, June 30, March 31, 2023 (Unaudited, U.S.$ in millions) Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) / Phoenix Holdings Ltd. - SC 13-G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Teva Pharmaceutical Industries Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.10 per share (Title of Class of Securities) 881624209 (CUSIP Number) April 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

April 8, 2024

April 8, 2024 Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.

Employment Agreement, dated as of September 25, 2018, between Teva UK Limited and Richard Daniell *

Exhibit 10.23 Execution version EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of September 25, 2018, is entered into by and between TEVA UK LIMITED., a company incorporated in the United Kingdom (“Teva UK”), and RICHARD DANIELL (the “Executive”). R E C I T A L S: WHEREAS the Executive has been employed by Teva UK pursuant to a contract of employment dated 1 October 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from     to      Commission file number 0

Policy Relating to Recovery of Erroneously Awarded Compensation *

Exhibit 97 CLAWBACK POLICY TEVA PHARMACEUTICAL INDUSTRIES LTD. PURPOSE Teva Pharmaceutical Industries Ltd. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Company’s Board of Directors (the “Boa

Subsidiaries of the Registrant *

Exhibit 21 The following is a list of subsidiaries of the Company as of December 31, 2023, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.

Letter Agreement, dated as of February 11, 2022, between Teva Pharmaceuticals Europe and Richard Daniell *

Exhibit 10.24 Private and confidential February 9, 2022 To: Richard Daniell Subject: Extension letter to International Assignment Agreement dated March 7, 2017 (the “Agreement”) The parties mutually agree to extend the undersigned international assignment until March 15, 2024 (the “Extension Period”). All terms and conditions under the Agreement will remain the same during the Extension Period. Th

Notice of resolution of the Board of Directors of the Phoenix Holdings Ltd., dated as of December 12, 2019.

Exhibit 1 [Unofficial Translation] December 12, 2019 Powers of Signature in The Phoenix Holdings Ltd.

TEVJF / Teva Pharmaceutical Industries Limited / Phoenix Holdings Ltd. - SC 13-G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Teva Pharmaceutical Industries Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.10 per share (Title of Class of Securities) M8769Q102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Teva Reports Growth in Fourth Quarter and Full Year 2023

Exhibit 99.1 Teva Reports Growth in Fourth Quarter and Full Year 2023 2023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO® - exceeding $1.2 billion in annual revenues, up 28% from 2022; strong growth expected to continue in 2024 with expected revenues of ~$1.5 billion; AJOVY® - global annual revenues of $435 million, up 16% from 2022; Generics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2024 TEVA PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2024 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LI

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

Exhibit 99.1 Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance 2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO®, AJOVY® and global generics business: Growth of AUSTEDO in North America Growt

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 4, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpora

Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

EX-99.1 Exhibit 99.1  Press Release   Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment • TEV ‘574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease • Collaboration supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseases • Collaboration leverages the i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 TEVA PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorp

TEVA ANNOUNCES CHANGES TO EXECUTIVE MANAGEMENT TEAM

EX-99.1 Exhibit 99.1 TEVA ANNOUNCES CHANGES TO EXECUTIVE MANAGEMENT TEAM TEL AVIV, Israel & PARSIPPANY, N.J., September 28, 2023 — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Glo

Deferred Prosecution Agreement with the U.S. Department of Justice, dated August 21, 2023 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on August 24, 2023)

EX-10.1 Exhibit 10.1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA UNITED STATES OF AMERICA ) ) Criminal No. 2:20-cr-200-RBS(s) ) v. ) ) Violations: 15 U.S.C. § 1 TEVA PHARMACEUTICALS USA, INC., ) (conspiracy to restrain trade – ) 3 counts) Defendant. ) ) DEFERRED PROSECUTION AGREEMENT The United States Department of Justice, Antitrust Division (“United States”) and TEVA PHARMACEUT

TEVA SETTLES PRICE FIXING CHARGES WITH U.S. DOJ

Exhibit 99.1 TEVA SETTLES PRICE FIXING CHARGES WITH U.S. DOJ TEL AVIV, Israel & PARSIPPANY, N.J, August 21, 2023 – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal price-fixing charges brought against Teva in 2020. Under the DPA, wh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 21, 2023 TEVA PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 21, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpora

Teva Reports Second Quarter 2023 Financial Results

Exhibit 99.1 Teva Reports Second Quarter 2023 Financial Results Revenues of $3.9 billion GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56 Cash flow generated from operating activities of $324 million Free cash flow of $632 million AUSTEDO® U.S. revenues of $308 million 2023 revenues outlook revised to $15.0-$15.4 billion from $14.8-$15.4 billion; all other key components reaffirmed: Non-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2023 TEVA PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT T

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Global Opioids Settlement Agreement, effective on August 7, 2023, between Teva Pharmaceutical Industries Ltd. and the states, subdivisions and special districts named therein (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023)

EX-10.1 Table of Contents Exhibit 10.1 TEVA GLOBAL OPIOID SETTLEMENT AGREEMENT I. Definitions 2 II. Participation by States and Condition to Preliminary Agreement 17 III. Cessation of Litigation Activities 18 IV. Injunctive Relief 19 V. Release 19 VI. Monetary Relief Overview and Maximum Payments 24 VII. Annual Payments to Settlement Fund 25 VIII. Allocation and Use of Settlement Funds 36 IX. Sett

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2023 TEVA PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2023 TEVA PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorporati

TEVJF / Teva- Pharmaceutical Industries Ltd. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Teva Pharmaceutical Industries Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M8769Q102 (CUSIP Number) May 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 TEVA PHARMACEUTICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction of Incorporation) (C

TEVA CONCLUDES NATIONWIDE OPIOIDS SETTLEMENT AGREEMENT

EX-99.1 Exhibit 99.1 TEVA CONCLUDES NATIONWIDE OPIOIDS SETTLEMENT AGREEMENT • Settles with all 50 states and 99 percent of litigating subdivisions • Shipments of life-saving generic Narcan® (naloxone hydrochloride nasal spray) have already begun; payments to states to begin in the second half of 2023 • Separate settlement reached with the final state of Nevada TEL AVIV, Israel & PARSIPPANY, N.J.,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdict

SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 124 Dvora HaNevi’a St., Tel Aviv, Israel 6944020 (

Exhibit 1.01 – Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form

EX-1.01 Exhibit 1.01 Teva Pharmaceutical Industries Limited Conflict Minerals Report For the Year Ended December 31, 2022 This Specialized Disclosure Report on Form SD of Teva Pharmaceutical Industries Limited for the year ended December 31, 2022 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 d505198ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 TEVA PHARMACEUTICAL IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITE

Letter Agreement, dated as of February 8, 2023, between Teva Pharmaceutical Industries Ltd. and Eric Drapé *

EX-10.1 Exhibit 10.1 February 8, 2023 To: Eric Drape Dear Eric, I am pleased to inform you that in recognition of your importance and criticality to the success of the Teva Group, the Board of Directors and its Compensation Committee approved granting you with the following additional terms. ◾ Certain continued vesting benefits: In the event you are terminated by the Company without cause (as defi

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

Exhibit 99.1 Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook TEL AVIV, Israel-(BUSINESS WIRE)-May 10, 2023-Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023. Revenues of $3.7 billion GAAP loss per share of $0.18 Non-GAAP diluted EPS of $0.40 Cash flow used in operating activities of $145 milli

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2023 TEVA PHARMACEUTICAL I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Consent of Van Doorne, N.V. (included in Exhibit 5.3)

EX-5.3 Exhibit 5.3 Teva Pharmaceutical Finance Netherlands II B.V. Teva Pharmaceutical Finance Netherlands III B.V. Jachthavenweg 121 1081 KM Amsterdam P.O. Box 75265 1070 AG Amsterdam the Netherlands c/o Teva Pharmaceutical Industries Limited 124 Dvora Hanevi’a Street Tel Aviv, 6944020 Israel T +31 20 6789 123 F +31 20 6789 589 Date 9 March 2023 Our ref. 40.00.3172 Subject Registration Statement

Fourth Supplemental Senior Indenture, dated as of March 9, 2023, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent, including the form of the 7.375% Sustainability-Linked Senior Notes due 2029 and the form of the 7.875% Sustainability-Linked Senior Notes due 2031 (incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K filed with the SEC on March 9, 2023)

EX-4.2 Exhibit 4.2 TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, THE BANK OF NEW YORK MELLON, as Trustee and THE BANK OF NEW YORK MELLON, LONDON BRANCH, as Paying Agent FOURTH SUPPLEMENTAL SENIOR INDENTURE Dated as of March 9, 2023 to the Senior Indenture dated as of March 14, 2018 Creating the series of Securities (as defined her

Fourth Supplemental Senior Indenture, dated as of March 9, 2023, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee, including the form of the 7.875% Sustainability-Linked Senior Notes due 2029 and the form of the 8.125% Sustainability-Linked Senior Notes due 2031 (incorporated by reference to Exhibit 4.6 to Current Report on Form 8-K filed with the SEC on March 9, 2023)

EX-4.6 Exhibit 4.6 TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, and THE BANK OF NEW YORK MELLON, as Trustee FOURTH SUPPLEMENTAL SENIOR INDENTURE Dated as of March 9, 2023 to the Senior Indenture dated as of March 14, 2018 Creating the series of Securities (as defined herein) designated 7.875% Sustainability-Linked Senior Notes d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2023 TEVA PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or other Jurisdiction of Incorporation Or

Underwriting Agreement, dated as of March 1, 2023, among the Issuers, the Company, Citigroup Global Markets Europe AG, Citigroup Global Markets Inc., Goldman Sachs Bank Europe SE, Mizuho Securities Europe GMBH, Mizuho Securities USA LLC, MUFG Securities (Europe) N.V., MUFG Securities Americas Inc. and PNC Capital Markets LLC as representatives for the underwriters named in Schedule 1 annexed thereto.

EX-1.1 Exhibit 1.1 TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. €800,000,000 7.375% Sustainability-Linked Senior Notes due 2029 €500,000,000 7.875% Sustainability-Linked Senior Notes due 2031 TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. $600,000,000 7.875% Sustainability-Linked Senior Notes due 2029 $500,000,000 8.125% Sustainability-Linked Senior Notes due 2031 Payment of principal and int

Proceeds to Repay Existing Debt

EX-99.1 Exhibit 99.1 Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer Proceeds to Repay Existing Debt TEL AVIV—(BUSINESS WIRE)—March 1, 2023— Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering

You’ve Exceeded the SEC’s Traffic Limit

EX-FILING FEES Exhibit 107 CALCULATION OF THE REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price per Security Proposed Maximum Aggregate Offering Price Amount of Registration Fee €800,000,000 7.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2023 TEVA PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or other Jurisdiction of Incorporation Or

$2,490,000,000 (equivalent) Teva Pharmaceutical Finance Netherlands II B.V. € 800,000,000 7.375% Sustainability-Linked Senior Notes due 2029 € 500,000,000 7.875% Sustainability-Linked Senior Notes due 2031 Teva Pharmaceutical Finance Netherlands III

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260519 PROSPECTUS SUPPLEMENT (To Prospectus dated October 27, 2021) $2,490,000,000 (equivalent) Teva Pharmaceutical Finance Netherlands II B.V. € 800,000,000 7.375% Sustainability-Linked Senior Notes due 2029 € 500,000,000 7.875% Sustainability-Linked Senior Notes due 2031 Teva Pharmaceutical Finance Netherlands III B.V.

FREE WRITING PROSPECTUS DATED MARCH 1, 2023 (To the Prospectus dated October 27, 2021, as supplemented by the Preliminary Prospectus Supplement dated February 27, 2023) Teva Pharmaceutical Finance Netherlands II B.V. €800,000,000 7.375% Sustainabilit

FWP ISSUER FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration No. 333-260519 March 1, 2023 FREE WRITING PROSPECTUS DATED MARCH 1, 2023 (To the Prospectus dated October 27, 2021, as supplemented by the Preliminary Prospectus Supplement dated February 27, 2023) Teva Pharmaceutical Finance Netherlands II B.V. €800,000,000 7.375% Sustainability-Linked Senior Notes due 2029 €500,000,000 7.

Subject to Completion Preliminary Prospectus Supplement, dated February 27, 2023

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260519 Information in this preliminary prospectus supplement is not complete and may be changed. The definitive terms of the transactions described herein will be described in the final version of this document. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securiti

TEVJF / Teva Pharmaceutical Industries Ltd. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Teva Pharmaceutical Industries Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M8769Q102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the

Letter Agreement, dated November 21, 2022, between Teva Pharmaceutical Industries Limited and Kåre Schultz *

EX-10.7 Exhibit 10.7 EXECUTION VERSION November 21, 2022 Kåre Schultz c/o Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi’a Street, Tel Aviv, Israel Dear Kåre: This letter memorializes our recent discussions regarding your departure from the position of President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. (the “Company”) and the appointment of your successor, who is ex

Amendment to Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated as of February 6, 2023, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Finance Netherlands II B.V. and Teva Pharmaceutical Finance Netherlands III B.V., as borrowers, Bank of America, N.A. and the certain other lenders party thereto (incorporated by reference to Exhibit 10.3 to Annual Report on Form 10-K filed with the SEC on February 10, 2023)

EX-10.3 Exhibit 10.3 AMENDMENT TO SENIOR UNSECURED SUSTAINABILITY-LINKED REVOLVING CREDIT AGREEMENT This AMENDMENT to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated as of February 6, 2023 (this “Amendment”), is made and entered into by and among TEVA PHARMACEUTICAL INDUSTRIES LIMITED, an Israeli company registered under no 52-0013-954, the registered address of which

Employment Agreement, dated November 21, 2022, between Teva Pharmaceutical Industries Limited and Richard D. Francis (incorporated by reference to Exhibit 10.6 to Annual Report on Form 10-K filed with the SEC on February 10, 2023)

EX-10.6 Exhibit 10.6 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered on this 21st day of November 2022, and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 124 Dvora HaNevi’a Street, Tel Aviv, Israel, Company No. 52-001395-4 (the “Company”), and Richard Francis (“Executive”). WHEREAS, the Company wishes to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-16174

Letter Agreement, dated as of December 27, 2022, between Teva Pharmaceutical Industries and Eric Drape *

EX-10.31 Exhibit 10.31 December 12, 2022 Private and confidential To: Eric Drape Subject: Extension letter to International Assignment as stated in Employment Agreement dated March 12, 2020 (the “Agreement”) The parties mutually agree to extend the undersigned international assignment until January 1, 2025 (the “Extension Period”). All terms and conditions under the Agreement will remain the same

Subsidiaries of the Registrant *

EX-21 Exhibit 21 The following is a list of subsidiaries of the Company as of December 31, 2022, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.

SECOND AMENDED AND RESTATED DEPOSIT AGREEMENT by and among TEVA PHARMACEUTICAL INDUSTRIES LIMITED CITIBANK, N.A., as Depositary, THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of December 4, 2018 TABLE OF CO

Exhibit (a) SECOND AMENDED AND RESTATED DEPOSIT AGREEMENT by and among TEVA PHARMACEUTICAL INDUSTRIES LIMITED and CITIBANK, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2023 TEVA PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2023 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS

/s/ Jean-Claude Lanza

Exhibit (d) February 8, 2023 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity to be created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under

Rule 466 Certification

Exhibit (e) Rule 466 Certification The depositary, Citibank, N.A., represents and certifies the following: (i) That it had previously filed a registration statement on Form F-6 (Registration No. 333-228351) with respect to Teva Pharmaceutical Industries Limited, which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this For

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

Exhibit 99.1 Teva Reports Fourth Quarter and Full Year 2022 Financial Results TEL AVIV, Israel-(BUSINESS WIRE)-February 8, 2023-Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2022. Q4 and FY 2022 highlights: Q4 2022 FY 2022 Revenues $3.9 billion $14.9 billion GAAP diluted loss per share $(1.10) $(2.12) Non-GAAP dilut

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of issuer

As filed with the Securities and Exchange Commission on February 8, 2023 Registration No.

* * * * * *

CORRESP 1 filename1.htm December 20, 2022 Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Li Xiao and Frank Wyman Re: Teva Pharmaceutical Industries Limited Form 10-K for the Fiscal Year Ended December 31, 2021 filed February 9, 2022 Form 8-K Dated November 3, 2022 File No. 001-16174 Ladies and Gentlemen: O

Teva Announces Appointment of Richard Francis as President and CEO Kåre Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future

Exhibit 99.1 Teva Announces Appointment of Richard Francis as President and CEO K?re Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future TEL AVIV, Israel ? November 21, 2022 ? Teva Pharmaceutical Industries Ltd. (?Teva? or the ?Company?) (NYSE and TASE: TEVA), today announced that the Company?s Board of Directors has appointed Richard Francis as Presi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LI

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS

Teva Reports Third Quarter 2022 Financial Results

Exhibit 99.1 Teva Reports Third Quarter 2022 Financial Results Key financial highlights and outlook Revenues of $3.6 billion GAAP diluted EPS of $0.05 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $543 million Free cash flow of $685 million 2022 revenues outlook revised mainly due to continued foreign exchange headwinds; non-GAAP tax rate outlook range revised to 1

* * * * * *

CORRESP 1 filename1.htm October 26, 2022 Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Li Xiao and Frank Wyman Re: Teva Pharmaceutical Industries Limited Form 10-K for the Fiscal Year Ended December 31, 2021 filed February 9, 2022 File No. 001-16174 Ladies and Gentlemen: On behalf of Teva Pharmaceutical I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of re

Teva Reports Second Quarter 2022 Financial Results

Exhibit 99.1 Teva Reports Second Quarter 2022 Financial Results Teva has reached agreement in principle on the primary financial terms of a nationwide opioids settlement and has revised its provision to reflect its terms Key financial highlights and outlook Revenues of $3.8 billion GAAP diluted loss per share of $0.21 Non-GAAP diluted EPS of $0.68 Cash flow generated from operating activities of $

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 26, 2022 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS Em

Articles of Association (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the SEC on June 23, 2022)

Exhibit 3.1 ARTICLES OF ASSOCIATION of TEVA PHARMACEUTICAL INDUSTRIES LIMITED A Limited Liability Company Updated on June 23, 2022 TABLE OF CONTENTS A. INTRODUCTION 3 Interpretation 3 Objectives and Purpose of the Company 3 Limitation of Liability 3 B. CAPITAL OF THE COMPANY 3 Capital Structure 3 Share Certificates 5 Transfer and Endorsement of Shares 5 Increase and Issue of the Registered Capital

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2022 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or other jurisdiction of Incorporati

Teva Pharmaceutical Industries Limited Conflict Minerals Report For the Year Ended December 31, 2021

Exhibit 1.01 Teva Pharmaceutical Industries Limited Conflict Minerals Report For the Year Ended December 31, 2021 This Specialized Disclosure Report on Form SD of Teva Pharmaceutical Industries Limited (?Teva? or ?we?) for the year ended December 31, 2021 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule was adopted by the Securities and Exchan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdict

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 124 Dvora HaNevi?a St., Tel Aviv, Israel 6944020 (Add

Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated as of April 29, 2022, by and among Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Finance Netherlands II B.V. and Teva Pharmaceutical Finance Netherlands III B.V., as borrowers, Bank of America, N.A., as administrative agent, Bank of America Europe Designated Activity Company, as sustainability coordinator and documentation agent, and the lenders party thereto *

Exhibit 10.1 EXECUTION VERSION US$1,800,000,000 SENIOR UNSECURED SUSTAINABILITY-LINKED REVOLVING CREDIT AGREEMENT dated as of April 29, 2022 among TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. and TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V., as Borrowers, THE LENDERS PARTY HERETO FROM TIME TO TIME, and BANK OF AMERICA,

Teva Reports First Quarter 2022 Financial Results

Exhibit 99.1 Teva Reports First Quarter 2022 Financial Results Revenues of $3.7 billion GAAP diluted loss per share of $0.86 Non-GAAP diluted EPS of $0.55 Cash flow used in operating activities of $49 million Free cash flow of $117 million 2022 revenue outlook revised lower to reflect ongoing impact of foreign exchange fluctuations; COPAXONE? outlook revised lower mainly to reflect increased compe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITE

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2022 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS Empl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpo

TEVJF / Teva Pharmaceutical Industries Ltd. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Teva Pharmaceutical Industries Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M8769Q102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

Teva Reports Fourth Quarter and Full Year 2021 Financial Results

Exhibit 99.1 Teva Reports Fourth Quarter and Full Year 2021 Financial Results TEL AVIV, Israel-(BUSINESS WIRE)-February 9, 2022-Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2021. Q4 2021 and FY 2021 highlights: Q4 2021 FY 2021 Revenues $4.1 billion $15.9 billion GAAP diluted EPS $(0.14) $0.38 Non-GAAP diluted EPS $

Appointment Letter, dated as of July 27, 2021, of Mark Sabag (incorporated by reference to Exhibit 10.25 to Annual Report on Form 10-K filed with the SEC on February 9, 2022)

Exhibit 10.25 Private and Confidential July 27, 2021 To: Mark Sabag Teva Global ID: 31507 Dear Mark, Congratulations on your appointment as Executive Vice President, International Markets Commercial. Effective Date: August 15, 2021 Your compensation will remain the same as prior to your appointment and the terms shall be as determined in your current employment agreement. We strongly believe in th

Appointment Letter, dated as of July 27, 2021, of Sven Dethlefs *

Exhibit 10.26 Private and Confidential July 27, 2021 To: Sven Dethlefs Teva Global ID: 75279 Dear Sven, Congratulations on your appointment as Executive Vice President, North America Commercial. The following are the terms of your employment which shall be amended in light of your new position. The terms of your employment are subject to Teva Pharmaceutical Industries? Compensation Policy applicab

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUA

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-16174

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 9, 2022 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS

Employment Agreement, dated as of June 5, 2018, between Teva Pharmaceuticals USA, Inc. and Sven Dethlefs *

Exhibit 10.23 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of June 5, 2018 (the ?Execution Date?), is entered into by and between TEVA PHARMACEUTICALS USA, INC., a Delaware corporation (?Teva USA?), and SVEN DETHLEFS (the ?Executive?). R E C I T A L S: WHEREAS, Teva USA desires to employ the Executive and the Executive has indicated his willingness

Amendment to Employment Agreement between Teva Pharmaceuticals USA, Inc. and Sven Dethlefs, dated as of July 18, 2018 *

Exhibit 10.24 Amendment to the Employment Agreement dated June 5, 2018 by and between Teva Pharmaceuticals USA, Inc. and Sven Dethlefs This Amendment (this ?Amendment?) is made this day of July, 2018, by and among Teva Pharmaceuticals USA, Inc. and Sven Dethlefs (the ?Executive?) to the Employment Agreement entered into between the Company and Executive dated June 5, 2018 (the ?Agreement?). Wherea

Subsidiaries of the Registrant *

Exhibit 21 The following is a list of subsidiaries of the Company as of December 31, 2021, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpo

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other Jurisdiction of Incorpora

Third Supplemental Senior Indenture, dated as of November 9, 2021, among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited, The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent.

EX-4.2 2 d249996dex42.htm EX-4.2 Exhibit 4.2 EXECUTION VERSION TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, THE BANK OF NEW YORK MELLON, as Trustee and THE BANK OF NEW YORK MELLON, LONDON BRANCH, as Paying Agent THIRD SUPPLEMENTAL SENIOR INDENTURE Dated as of November 9, 2021 to the Senior Indenture dated as of March 14, 2018 Cre

Third Supplemental Senior Indenture, dated as of November 9, 2021, among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.

Exhibit 4.6 EXECUTION VERSION TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V., as Issuer, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, as Guarantor, and THE BANK OF NEW YORK MELLON, as Trustee THIRD SUPPLEMENTAL SENIOR INDENTURE Dated as of November 9, 2021 to the Senior Indenture dated as of March 14, 2018 Creating the series of Securities (as defined herein) designated 4.750% Sustainability-Linked S

Consent of Van Doorne, N.V. (included in Exhibit 5.3)

Exhibit 5.3 Teva Pharmaceutical Finance Netherlands II B.V. Teva Pharmaceutical Finance Netherlands III B.V. Jachthavenweg 121 1081 KM Amsterdam P.O. Box 75265 1070 AG Amsterdam the Netherlands c/o Teva Pharmaceutical Industries Limited 124 Dvora Hanevi?a Street Tel Aviv, 6944020 Israel T +31 20 6789 123 F +31 20 6789 589 Date 9 November 2021 Our ref. 40.00.3000 Subject Registration Statement on F

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other Jurisdiction of Incorpora

CALCULATION OF THE REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price per Security Proposed Maximum Aggregate Offering Price Amount of Registration Fee €1,100,000,000 3.750% Sus

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260519 CALCULATION OF THE REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price per Security Proposed Maximum Aggregate Offering Price Amount of Registration Fee ?1,100,000,000 3.750% Sustainability-Linked Senior Notes due 2027 ?1,100,000,000 100% ?1,100,000

Proceeds to Repay Existing Debt

Exhibit 99.1 Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes Proceeds to Repay Existing Debt TEL AVIV?(BUSINESS WIRE)?November 2, 2021? Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (?Teva?) announced today that it successfully upsized and priced approximately $5,000,000,000 (equivalent)

Underwriting Agreement, dated as of November 2, 2021, among the Issuers, the Company, BNP Paribas, BNP Paribas Securities Corp., BofA Securities Europe SA, BofA Securities, Inc., HSBC Bank plc and J.P. Morgan AG, as representatives for the underwriters named in Schedule 1 annexed thereto.

Exhibit 1.1 TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. ?1,100,000,000 3.750% Sustainability-Linked Senior Notes due 2027 ?1,500,000,000 4.375% Sustainability-Linked Senior Notes due 2030 TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. $1,000,000,000 4.750% Sustainability-Linked Senior Notes due 2027 $1,000,000,000 5.125% Sustainability-Linked Senior Notes due 2029 Payment of principal and in

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or other Jurisdiction of Incorpora

FREE WRITING PROSPECTUS DATED NOVEMBER 2, 2021 (To the Prospectus dated October 27, 2021, as supplemented by the Preliminary Prospectus Supplement dated October 27, 2021) Teva Pharmaceutical Finance Netherlands II B.V. €1,100,000,000 3.750% Sustainab

ISSUER FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration No. 333-260519 November 2, 2021 FREE WRITING PROSPECTUS DATED NOVEMBER 2, 2021 (To the Prospectus dated October 27, 2021, as supplemented by the Preliminary Prospectus Supplement dated October 27, 2021) Teva Pharmaceutical Finance Netherlands II B.V. ?1,100,000,000 3.750% Sustainability-Linked Senior Notes due 2027 ?1,500,000,0

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance VI, LLC Subordinated Indenture

Exhibit 25.8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (I

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance IV, LLC Subordinated Indenture

Exhibit 25.4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance V, LLC Subordinated Indenture

Exhibit 25.6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance VI, LLC Senior Indenture

Exhibit 25.7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands II B.V. Senior Indenture

EX-25.9 Exhibit 25.9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York (Juris

Teva Reports Third Quarter 2021 Financial Results

Exhibit 99.1 Teva Reports Third Quarter 2021 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.26 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $529 million Free cash flow of $795 million Full year 2021 business outlook reaffirmed Net revenues of $16.0 - $16.4 billion Adjusted EBITDA of $4.8 - $5.1 billion EPS of $2.50 - $2.70 Free cash flow of $2.0

As filed with the Securities and Exchange Commission on October 27, 2021

Table of Contents As filed with the Securities and Exchange Commission on October 27, 2021 Registration No.

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands III B.V. Senior Indenture

Exhibit 25.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the Senior Indenture, dated as of March 14, 2018, by and among Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee

EX-25.16 21 d242199dex2516.htm EX-25.16 Exhibit 25.16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specifie

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance V, LLC Senior Indenture

Exhibit 25.5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Industries Limited Senior Indenture

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Subject to Completion Preliminary Prospectus Supplement, dated October 27, 2021

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-260519 Information in this preliminary prospectus supplement is not complete and may be changed. The definitive terms of the transactions described herein will be described in the final version of this document. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LI

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance IV, LLC Senior Indenture

Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the Senior Indenture, dated as of March 14, 2018, by and among Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Industries Limited and The Bank of New York Mellon, as trustee.

Exhibit 25.15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands III B.V. Subordinated Indenture

Exhibit 25.12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Industries Limited Subordinated Indenture

Exhibit 25.2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju

Consent of Van Doorne, N.V. (included in Exhibit 5.3)

Exhibit 5.3 Jachthavenweg 121 1081 KM Amsterdam Teva Pharmaceutical Finance Netherlands II B.V. Teva Pharmaceutical Finance Netherlands III B.V. P.O. Box 75265 1070 AG Amsterdam the Netherlands Teva Pharmaceutical Finance Netherlands IV B.V. c/o Teva Pharmaceutical Industries Limited 124 Dvora Hanevi?a Street Tel Aviv, 6944020 Israel Date 27 October 2021 Our ref. 40.00.3000 Subject Registration St

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands IV B.V. Senior Indenture

Exhibit 25.13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands II B.V. Subordinated Indenture

Exhibit 25.10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

Statement of Eligibility of The Bank of New York Mellon on Form T-1, as Trustee for the form of the Teva Pharmaceutical Finance Netherlands IV B.V. Subordinated Indenture

Exhibit 25.14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (J

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 26, 2021 TEVA PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 26, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpora

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT T

Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Teva Reports Second Quarter 2021 Financial Results

Exhibit 99.1 Teva Reports Second Quarter 2021 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.19 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $218 million Free cash flow of $625 million 2021 revenue outlook revised lower to reflect ongoing impact of COVID-19; all other key components reaffirmed: Net revenues of $16.0 - $16.4 billion vs. previous

Teva Announces Changes to Executive Management Team

Exhibit 99.1 Teva Announces Changes to Executive Management Team TEL AVIV, Israel & PARSIPPANY, N.J.-(BUSINESS WIRE)-July 21, 2021-Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Brendan O?Grady, Executive Vice President, North America Commercial, will leave Teva to pursue a career opportunity outside of the pharmaceutical industry, and Sve

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 21, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS Em

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 2, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorporatio

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdict

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 5 Basel Street, P.O. Box 3190, Petach Tikva, Israel 4

Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.

Exhibit 1.01 Teva Pharmaceutical Industries Limited Conflict Minerals Report For the Year Ended December 31, 2020 As would be expected, the COVID-19 pandemic has caused us to make certain adjustments in the manner at which we operate our business. The degree to which we have made these adjustments has varied based on regional and local mandates and recommendations, including quarantines, stay at h

Teva Reports First Quarter 2021 Financial Results

Exhibit 99.1 Teva Reports First Quarter 2021 Financial Results Revenues of $4.0 billion GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.63 Cash flow used in operating activities of $405 million Free cash flow of $59 million Full year 2021 business outlook reaffirmed: Net revenues of $16.4-16.8 billion EBITDA of $4.8 - $5.1 billion EPS of $2.50 - $2.70 Free cash flow of $2.0 - $2.3 billion TEL

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS E

Quarterly Report - 10-Q

Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

2

April 15, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Division of Corporation Finance, Office of Life Sciences Re: Teva Pharmaceutical Industries Limited Form 10-K for the Fiscal Year Ended December 31, 2020 filed February 10, 2021 (the ?2020 Form 10-K?) File No. 001-16174 Dear Ms. Mast and Ms. Conway: On behalf of Teva Pharmaceutical Industries Limited

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Teva Pharmaceutical Industries Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M8769Q102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMERICAN WELL CORPORATION (Name of Issuer) Class A Common Stock (Title of Class of Securities) (CUSIP Numbe

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Annual Report - FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-16174

Employment Agreement, dated as of March 12, 2020, between Teva Pharmaceutical Industries Limited and Eric Drapé *

EX-10.7 Exhibit 10.7 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered on March 12, 2020, and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 5 Basel Street, Petach Tikva, Israel, Company No. 52-001395-4 (the “Company”, “Teva”), and Eric Drapé (“Executive”). WHEREAS, the Company wishes to employ Executive as

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

Exhibit 99.1 Teva Reports Fourth Quarter and Full Year 2020 Financial Results TEL AVIV, Israel-(BUSINESS WIRE)-February 10, 2021-Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2020. Q4 2020 and FY 2020 highlights: Q4 2020 FY 2020 Revenues $4.5 billion $16.7 billion Cash flow from operating activities $331 million $1,

Subsidiaries of the Registrant *

EX-21 Exhibit 21 The following is a list of subsidiaries of the Company as of December 31, 2020, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.

Employment Agreement, dated as of May 30, 2013, between Teva Sante and Eric Drapé*

EX-10.8 Exhibit 10.8 CONTRAT DE TRAVAIL A DUREE INDETERMINEE ENTRE LES SOUSSIGNES : La société TEVA SANTE, société par actions simplifiée au capital de 109.599.592 Euros dont le siège social est sis 110 Esplanade du Général de Gaulle, Paris La Défense Cedex (92931), France, immatriculée sous le numéro 401 972 476 au RCS de Nanterre, représentée par Sima de Cayron, agissant en sa qualité de Directe

Transfer Agreement of Employment Contract, dated as of March 20, 2020, between Teva Sante, Teva Pharmaceutical Industries Limited and Eric Drapé *

EX-10.9 Exhibit 10.9 CONVENTION DE TRANSFERT DU CONTRAT DE TRAVAIL (Ci-après la “Convention”) TRANSFER AGREEMENT OF THE EMPLOYMENT CONTRACT (Hereinafter the “Agreement”) ENTRE LES SOUSIGNEES : BETWEEN THE UNDERSIGNED: La société TEVA SANTE, société par actions simplifiée dont le siège social est sis 110 Esplanade du General de Gaulle, Paris La Défense Cedex (92931), France, immatriculée sous le nu

Results of Operations and Financial Condition - TEVA PHARMACEUTICAL INDUSTRIES LIMITED 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 10, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IR

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* TEVA PHARMACEUTICAL INDUSTRIES LTD (Name of Issuer) Common Stock (Title of Class of Securities) M8769Q102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpora

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 21, 2021 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorpora

Teva Reports Third Quarter 2020 Financial Results

Exhibit 99.1 Teva Reports Third Quarter 2020 Financial Results Revenues of $4.0 billion GAAP diluted loss per share of $3.97 Non-GAAP diluted EPS of $0.58 Free cash flow of $506 million Full year 2020 business outlook revised: Net revenues of $16.5-16.8 billion EBITDA of $4.7 - $4.9 billion EPS of $2.40 - $2.55 Free cash flow of $1.8 - $2.2 billion TEL AVIV, Israel-(BUSINESS WIRE)-November 5, 2020

Teva Pharmaceutical Industries Limited Israeli Subplan of Teva’s 2020 Long-Term Equity-Based Incentive Plan (incorporated by reference to Exhibit 10.3 to Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020)

EX-10.3 Exhibit 10.3 TEVA PHARMACEUTICAL INDUSTRIES LIMITED ISRAELI SUBPLAN OF THE 2020 LONG-TERM EQUITY-BASED INCENTIVE PLAN 1. PURPOSE The purpose of this subplan (the “Israeli Subplan”) is to supplement the Teva Pharmaceutical Industries Limited 2020 Long-Term Equity-Based Incentive Plan (the “Plan”) in setting the framework for the grant of Awards to Israeli 102 Participants (as such term is d

Results of Operations and Financial Condition - TEVA PHARMACEUTICAL INDUSTRIES LIMITED 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2020 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) Israel 001-16174 00-0000000 (State or Other Jurisdiction (Commission (IRS

Form Award Agreement under Teva’s 2020 Long-Term Equity-Based Incentive Plan (incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020)

EX-10.2 Exhibit 10.2 AWARD AGREEMENT This Award Agreement (this “Agreement”), is made effective as of [•], between Teva Pharmaceutical Industries Limited (the “Company”) and [•] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2020 Long-Term Equity-Based Incentive Plan (the “Plan”). Pursuant to Sections 6, 7 and

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LI

Teva Pharmaceutical Finance Netherlands II B.V. Exchange Offer for 6.000% Senior Notes due 2025 Teva Pharmaceutical Finance Netherlands III B.V. Exchange Offer for 7.125% Senior Notes due 2025 Offering Price: 100%

424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-241010 333-241010-01 333-241010-02 Prospectus Teva Pharmaceutical Finance Netherlands II B.V. Exchange Offer for 6.000% Senior Notes due 2025 Teva Pharmaceutical Finance Netherlands III B.V. Exchange Offer for 7.125% Senior Notes due 2025 Offering Price: 100% Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance

Teva Pharmaceutical Industries Limited Conflict Minerals Report For the Year Ended December 31,

EX-1.01 Exhibit 1.01 Teva Pharmaceutical Industries Limited Conflict Minerals Report For the Year Ended December 31, 2019 As would be expected, the COVID-19 pandemic has caused us to make certain adjustments in the manner at which we operate our business. The degree to which we have made these adjustments has varied based on regional and local mandates and recommendations, including quarantines, s

- FORM SD

Form SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) ISRAEL 001-16174 N/A (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 5 Basel Street, P.O. Box 3190, Petach Tikva,

-

CORRESP Teva Pharmaceutical Industries Limited 5 Basel Street P.O. Box 3190 Petach Tikva, 4951033 Israel August 13, 2020 Via EDGAR Submission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re Teva Pharmaceutical Industries Limited Registration Statement on Form S-4 (File No. 333-241010) Ladies and Gentlemen: Pursuant to Rule 461 of the

-

CORRESP 1 filename1.htm CONFIDENTIAL FOR COMMISSION USE ONLY Teva Pharmaceutical Industries Limited 5 Basel Street P.O. Box 3190 Petach Tikva, 4951033 Israel August 13, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Re: Teva Pharmaceutical Industries Limited Registration Statement on Form S-4 File No. 333-241010

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2020 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrants as specified in its charter) Israel 001-16174 Not Applicable (State or Other Jurisdiction of Incorporat

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Teva Reports Second Quarter 2020 Financial Results

Exhibit 99.1 Teva Reports Second Quarter 2020 Financial Results Revenues of $3.9 billion GAAP diluted EPS of $0.13 Non-GAAP diluted EPS of $0.55 Free cash flow of $582 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion TEL AVIV, Israel-(BUSINESS WIRE)-August 5, 2020-Teva Ph

Subsidiaries of Teva Pharmaceutical Industries Limited

EX-21.0 Exhibit 21.0 The following is a list of subsidiaries of the Company, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Name of Subsidiary Jurisdiction of Organization Actavis Pharma Holding 4 ehf Iceland Allergan UK Group limited United Kingdom Medis ehf. Iceland Mepha Schweiz AG Switzerland Merckle GmbH Germany Norton (Waterford)

- S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on August 5, 2020 Registration No.

- S-8

S-8 As filed with the Securities and Exchange Commission on August 5, 2020 Registration No.

Consent of Tulchinsky Stern Marciano Cohen Levitski & Co. (included in Exhibit 5.3)

EX-5.3 Exhibit 5.3 * Member of the N.Y. Bar Association August 5, 2020 Teva Pharmaceutical Industries Limited Teva Pharmaceutical Finance Netherlands II B.V. Teva Pharmaceutical Finance Netherlands III B.V. c/o Teva Pharmaceutical Industries Limited 5 Basel Street P.O. Box 3190 Petach Tikva 4951033 Israel Ladies and Gentlemen: We have acted as Israeli counsel for Teva Pharmaceutical Industries Lim

Kesselman & Kesselman Preferability Letter dated August 5, 2020 (incorporated by reference to Exhibit 18 to Quarterly Report on Form 10-Q filed with the SEC on August 5, 2020)

EX-18 Exhibit 18 August 5, 2020 Board of Directors Teva Pharmaceutical Industries Ltd.

- S-4

S-4 Table of Contents As filed with the Securities and Exchange Commission on August 5, 2020 No.